Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
暂无分享，去创建一个
J. Wanders | J. Beijnen | J. Smyth | C. Twelves | C. van Kesteren | J. Jimeno | J. Vermorken | A. Anthoney | Cecilia Guzman | C. Guzmán | A. Bowman | K. Hoekman | A. Hanauske | C. Kesteren | J. Uiters | J. Gómez | Jantien Wanders | Jos H. Beijnen | Chris Twelves | John F. Smyth | José M. Gómez | J. Wanders | J. Beijnen | J. F. Smyth